Cytori Aims for $10M Through Subscription Agreements SaleFriday, May 30, 2014
San Diego regenerative medicine company Cytori Therapeutics Inc. has entered into subscription agreements with some of its institutional investors to raise about $10 million.
Cytori (Nasdaq: CYTX) will issue and sell about 4 million shares to the investors at $2.47 per unit. Its stock closed at $2.41 May 30.
The company, which is developing cell therapies for heart disease and other disorders, said it plans to use the proceeds for general corporate purposes.